Pharmaceutical intermediates
OSIMERTINIB MESYLATE Intermediates
9 pharmaceutical intermediates for OSIMERTINIB MESYLATE. Indication: Carcinoma, Non-Small-Cell Lung.
About OSIMERTINIB MESYLATE
- Originator
- AstraZeneca
- Indication
- Carcinoma, Non-Small-Cell Lung
- Approved Date
- 11/13/2015
- DS/DP
- 07/25/2032
Available intermediates
9 intermediates currently listed for OSIMERTINIB MESYLATE. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-fluoro-2-Methoxy-5-nitroaniline | 1075705-01-9 | / | / |
| 3-(2-chloropyriMidin-4-yl)-1-Methylindole | 1032452-86-0 | / | / |
| N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine | 1421372-94-2 | / | / |
| 1,4-BenzenediaMine, N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitro- | 1421372-67-9 | / | / |
| N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]benzene-1,2,4-triamine | 1421372-66-8 | / | / |
| N,N,N'-Trimethylethylenediamine | 142-25-6 | / | / |
| 4-Methoxy-5-(3-morpholinopropoxy)-2-nitrobenzonitrile | 675126-26-8 | / | / |
| N-(3-Chloropropyl)morpholine | 7357-67-7 | / | / |
| 5-hydroxy-4-methoxy-2-nitrobenzoic acid ethyl ester | 1146162-38-0 | / | / |
Other programs under O
Building toward OSIMERTINIB MESYLATE?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →